1327 Results for "

Aggregation

" in MedChemExpress (MCE) Product Catalog:
Products (1327)

1327 Results for "Aggregation" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-W020033
CAS No.: 79-63-0
Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-B0512
CAS No.: 127-79-7
Synonyms: RP2632
Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-120821
CAS No.: 1839524-44-5
Purity:  99.17%
Synonyms: ES2
Target:  

Exosomes

Research Areas:  

Others

Endosidin-2 (ES2) is a selective inhibitor targeting the conserved exosome subunit EXO70. Endosidin-2 binds to the C-terminal domain of EXO70, inhibiting exocytosis and endosomal recycling, while promoting vacuolar trafficking in plant cells. Endosidin-2 interferes with the EXO70-mediated vesicle-to-plasma membrane anchoring process, leading to abnormal aggregation of auxin transporters (such as PIN2) in the cytoplasm and redirected to vacuolar degradation, while causing abnormal Golgi structure (such as cup-shaped or ring-shaped vesicles cisternae formation). Endosidin-2 can inhibit exocytosis in plant and mammalian cells and is mainly used to study the dynamic regulation of membrane trafficking (such as polar growth, vesicle sorting) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-78263
CAS No.: 1485-00-3
Synonyms: NSC 170724; 5-(2-Nitrovinyl)benzodioxole
MNS (NSC 170724), the beta-nitrostyrene derivative, is an orally active tyrosine kinase inhibitor, a broad-spectrum antiplatelet agent, and a PANoptosis inhibitor. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively. MNS inhibits NLRP3 inflammasome and β1 integrin. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS is cytotoxic to a variety of cells .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B0523A
CAS No.: 58579-51-4
Synonyms: BL4162A
Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P3414A
Target:  

Proteasome

Research Areas:  

Neurological Disease

Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P0074
CAS No.: 67869-62-9
Synonyms: Gly-Pro-Arg-Pro; Pefa 6003
Target:  

Thrombin

Research Areas:  

Cardiovascular Disease

GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-10835
CAS No.: 861238-35-9
Purity:  99.61%
Research Areas:  

Cardiovascular Disease

DG-041 is a potent, high affinity and selective EP3 receptor antagonist with IC50s of 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively. DG-041 inhibits PGE2 facilitation of platelet aggregation. DG-041 crosses the blood-brain barrier .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B0523
CAS No.: 68475-42-3
Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-100386
CAS No.: 55142-85-3
Purity:  99.56%
Synonyms: PCR 5332
Target:  

NTPDase Cytochrome P450

Research Areas:  

Cardiovascular Disease

Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-144390
CAS No.: 1327156-14-8
Purity:  99.78%
Synonyms: GPVI antagonist 1
Target:  

Glycoprotein VI

Research Areas:  

Cardiovascular Disease

(S)-S007-1558 (compound 5) is a glycoprotein VI (GPVI) platelet receptor antagonist. (S)-S007-1558 inhibits collagen-induced platelet aggregation with an IC50 of 25.3 μM .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P9934
CAS No.: 143653-53-6
Synonyms: C7E3

Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-101308A
Purity:  99.6%
Target:  

P2Y Receptor

Research Areas:  

Cardiovascular Disease

MRS2179 tetrasodium hydrate is a competitive P2Y1 receptor antagonist, with a Kb of 102 nM and a pA2 of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC50=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium hydrate inhibits platelet aggregation .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15840
CAS No.: 1273323-67-3
Purity:  99.02%
Synonyms: C24
Target:  

AMPK

Research Areas:  

Cancer

YLF-466D is a newly developed AMPK activator, which inhibits platelet aggregation.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-112624
CAS No.: 9004-54-0
Synonyms: Dextran 40
Dextran (Dextran 40) has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12662
CAS No.: 1402727-29-0
Purity:  99.76%
Target:  

Microtubule/Tubulin

Research Areas:  

Neurological Disease

PE859 is a potent inhibitor of both tau and aggregation with IC50 values of 0.66 and 1.2 μM, respectively.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0785
CAS No.: 15291-76-6
Synonyms: BN-52022
Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-120475
CAS No.: 1232841-78-9
Synonyms: ATH434
Target:  

α-synuclein

Research Areas:  

Neurological Disease

PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-120475A
CAS No.: 2387898-69-1
Purity:  99.92%
Synonyms: ATH434 mesylate
Target:  

α-synuclein

Research Areas:  

Neurological Disease

PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-100957
CAS No.: 20153-98-4
Purity:  99.64%
Research Areas:  

Cardiovascular Disease

Dilazep dihydrochloride is an inhibitor of adenosine uptake. Dilazep dihydrochloride has cerebral and coronary vasodilating action through enhancement of effect of adenosine. Dilazep dihydrochloride also inhibits the ischemic damage, platelet aggregation, and membrane transport of nucleosides .
loading...
    loading...